IMPAKT breast cancer conference abstracts online

Xenografts and mathematical modelling; liquid biopsy; nanotechnology; next generation genomics- Science is running fast and the impact of new technologies in the care of patients with breast cancer will be at the core of the sixth edition of the IMPAKT conference on translational research in breast cancer.

Check the abstracts online (full text) as of Thursday, 24 April 2014 at 12:00 (CEST)

Poster highlights

  • Abstract 1P - Detection of breast cancer and abnormal mammograms with a rapid point-of-care breath test, M. Phillips
  • Abstract 5P - The clinical impact of using the IHC4 Score: our MDT experience in a prospective series of postmenopausal women with ER positive early breast cancer, B.J. Yeo
  • Abstract 11P - Optimal duration of cardiac monitoring in metastatic HER2 positive breast cancer patients receiving trastuzumab, K. Chiu
  • Abstract 14P - Adoption of multi-gene assays in HR+, HER2- breast cancer (BC) patients in Europe: results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey, M.S. Aapro
  • Abstract 17P - The BRCA cancer gene as a useful predictor for double primary breast and ovarian cancer: A meta-analysis, A. Sattaratnamai
  • Abstract 69P - Safety and efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT inhibitor) in patients with advanced breast cancer with PI3K pathway dependence, S. Gupta
  • Abstract 70P - Phase I/IIa study with CNS-targeted liposomal doxorubicin (2B3-101) in patients with brain metastases (BM) from breast cancer (BC) and other brain tumours, P.G. Aftimos

The conference will offer interesting discussions and presentations on the following topics:

  • Patient-derived tumour xenografts as models for breast cancer drug development: problems, pitfalls and future directions
  • Liquid biopsies: a convenient tool to monitor response and resistance to targeted therapies
  • Molecular sequencing: ethical, legal and social implications
  • Clinical implications of immune modulation in breast cancer
  • Dissecting cancer through mathematics: from the cell to the animal model

The full conference program is available at http://www.esmo.org/Conferences/IMPAKT-2014-Breast-Cancer/Programme

The IMPAKT Conference is co-organised by the Breast International Group (BIG) and the European Society for Medical Oncology (ESMO), in collaboration with a multidisciplinary alliance of European breast cancer organisations. Around 500 attendees are expected from throughout Europe and the rest of the world.

Media registration

BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues. Registered journalists can access all conference sessions and the IMPAKT Press Room.

Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the IMPAKT Media Policy: http://www.esmo.org/content/download/33257/666904/file/Impakt-2014-media-policy.pdf

To register for the event, please fill out the Complimentary Media Registration Form: http://www.formstack.com/forms/esmo-media_application_impakt_2014

Media registration in advance is strongly recommended although on-site registration will still be possible.

Press Room opening hours
Thursday, 8 May 2014 10:00 - 18:00
Friday, 9 May 2014 08:00 - 18:00
Saturday, 10 May 2014 08:00 - 13:00

Please contact the IMPAKT Press Office at [email protected] for any additional question.

IMPAKT Press Office
C/O ESMO Press Office
E-mail: [email protected]

Source: European Society for Medical Oncology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A novel approach to combatting prostate cancer